Saltar al contenido
Merck
  • Effect of phylloquinone (vitamin K1) supplementation for 12 months on the indices of vitamin K status and bone health in adult patients with Crohn's disease.

Effect of phylloquinone (vitamin K1) supplementation for 12 months on the indices of vitamin K status and bone health in adult patients with Crohn's disease.

The British journal of nutrition (2014-09-03)
Eibhlís M O'Connor, Geraldine Grealy, Jane McCarthy, Alan Desmond, Orla Craig, Fergus Shanahan, Kevin D Cashman
RESUMEN

Although epidemiological findings support a role for vitamin K status in the improvement of bone indices in adult patients with Crohn's disease (CD), this needs to be confirmed in double-blind, randomised controlled trials (RCT) with phylloquinone (vitamin K1). By conducting two RCT, the present study aimed to first establish whether supplementation with 1000 μg of phylloquinone daily near-maximally suppresses the percentage of undercarboxylated osteocalcin in serum (%ucOC; marker of vitamin K status) in adult patients with CD currently in remission as it does in healthy adults and second determine the effect of supplementation with phylloquinone at this dose for 12 months on the indices of bone turnover and bone mass. The initial dose-ranging RCT was conducted in adult patients with CD (n 10 per group) using 0 (placebo), 1000 or 2000 μg of phylloquinone daily for 2 weeks. In the main RCT, the effect of placebo v. 1000 μg vitamin K/d (both co-administered with Ca (500 mg/d) and vitamin D3 (10 μg/d)) for 12 months (n 43 per group) on the biochemical indices of bone turnover (determined by enzyme immunoassay) and bone mass (determined by dual-energy X-ray absorptiometry) were investigated. At baseline, the mean %ucOC was 47 %, and this was suppressed upon supplementation with 1000 μg of phylloquinone daily ( - 81 %; P< 0·01) and not suppressed further by 2000 μg of phylloquinone daily. Compared with the placebo, supplementation with 1000 μg of phylloquinone daily for 12 months had no significant effect (P>0·1) on bone turnover markers or on the bone mass of the lumbar spine or femur, but modestly increased (P< 0·05) the bone mass of the total radius. Despite near maximal suppression of serum %ucOC, supplementation with 1000 μg of phylloquinone daily (with Ca and vitamin D3) had no effect on the indices of bone health in adult CD patients with likely vitamin K insufficiency.

MATERIALES
Número de producto
Marca
Descripción del producto

Supelco
Colecalciferol, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Colecalciferol, ≥98% (HPLC)
Sigma-Aldrich
Vitamin K1, viscous liquid
Sigma-Aldrich
Vitamin K1, BioXtra, ≥99.0% (sum of isomers, HPLC), mixture of isomers
Sigma-Aldrich
Calcium, granular, 99%
Supelco
Colecalciferol (D3), analytical standard
Supelco
Phylloquinone (K1), analytical standard
USP
Colecalciferol, United States Pharmacopeia (USP) Reference Standard
Supelco
Vitamin K1, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
Vitamin D3 solution, 1 mg/mL in ethanol, ampule of 1 mL, certified reference material, Cerilliant®
Colecalciferol, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Calcium, dendritic pieces, purified by distillation, 99.99% trace metals basis
Sigma-Aldrich
Colecalciferol, meets USP testing specifications
Sigma-Aldrich
Calcium, turnings, 99% trace metals basis
Sigma-Aldrich
Calcium, pieces, <1 cm, 99%
Sigma-Aldrich
Colecalciferol, analytical standard
Sigma-Aldrich
Calcium, dendritic pieces, purified by distillation, 99.9% trace metals basis
Vitamin K1, European Pharmacopoeia (EP) Reference Standard